Brief: Geneuro: Protect-MS Phase 2 Trial Confirms Safety Of Higher Doses Of Temelimab In Multiple Sclerosis

Geneuro SA

21/03/2022 07:11

March 21 (Reuters) - Geneuro SA  GNRO.PA :
    * PROTECT-MS PHASE 2 TRIAL CONFIRMS SAFETY OF HIGHER DOSES
OF
TEMELIMAB AND SYNERGISTIC POTENTIAL TO ADDRESS NEURODEGENERATION
ON TOP OF ANTI-INFLAMMATORY TREATMENT IN MULTIPLE SCLEROSIS
    * PRIMARY ENDPOINT OF PROTECT-MS STUDY WAS MET: RESULTS
CONFIRM
EXCELLENT SAFETY PROFILE AND TOLERABILITY OF HIGHER DOSES OF
TEMELIMAB ADMINISTERED CONCOMITANTLY WITH A HIGH-EFFICACY
ANTI-INFLAMMATORY DRUG
    * OBSERVED EFFECT SIZES IN THIS NEW PATIENT POPULATION WERE
CONSISTENT WITH ONES SHOWN IN PREVIOUS CHANGE-MS AND ANGEL-MS
STUDIES
    * EFFICACY DATA, OBTAINED IN PATIENTS ALREADY EFFECTIVELY
TREATED
AGAINST INFLAMMATION, SHOWED THAT TEMELIMAB HAS A FAVORABLE
IMPACT ON KEY MRI PARAMETERS MEASURING NEURODEGENERATION 

Source text for Eikon:  ID:nBw9p0mxca 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))